

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Charles N. Serhan et al.

Serial No.: 10/663,061

Filed: September 12 2003

For: **ASPIRIN-TRIGGERED LIPID MEDIATORS**

Group Art Unit: 1621

Examiner: Kumar, Shailendra

Atty. Dkt. No.: **BWHI-031/US3**

Confirmation No.: 1985


Patent No.: 7,053,230

Issue Date: May 30, 2006

CERTIFICATE OF ELECTRONIC TRANSMISSION  
37 C.F.R. § 1.8I hereby certify that this correspondence is being  
electronically filed with the United States Patent and  
Trademark Office via EFS-Web on the date below:

November 5, 2010

Date

  
Barbara A. Avery**REQUEST FOR CERTIFICATE OF CORRECTION  
(UNDER 37 C.F.R. § 1.323)**ATTN: Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

Applicant hereby requests a Certificate of Correction for the above-identified patent under 37 C.F.R. § 1.323 to correct an error made by the USPTO, as presented on attached PTO Form-1050. Correction of the error presented herein does not involve a change in the patent which would constitute new matter or require re-examination.

Should the Examiner have any questions, please contact the undersigned attorney at (612) 321-2237 with any questions, comments or suggestions relating to the referenced patent.

CUSTOMER NUMBER **38824**

Respectfully submitted,

Colin L. Fairman  
Reg. No. 51,663  
Attorney for ApplicantFULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
Telephone: (612) 321-2237  
Facsimile (512) 536-4598  
Date: November 5, 2010

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE OF CORRECTION

PATENT NO.: 7,053,230  
DATE OF PATENT: May 30, 2006  
INVENTOR: Charles N. Serhan et al.

It is hereby certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 26 and lines 2 through 3 should be amended as follows:

acceptable salt, ester, [[B,]] prodrug, or –OR forms an amide and wherein P is a protecting group.

Column 26 and lines 17 through 19 should be amended as follows:

acceptable salt, ester, [[B,]] prodrug, or –OR forms an amide and wherein P is a hydrogen atom or a protecting group, such that the patient is treated.

**Customer Number 38824**

MAILING ADDRESS OF SENDER:

**PATENT NO.: 7,053,230**

FULBRIGHT & JAWORSKI LLP  
Attn: MNIPDOCKET  
600 Congress Avenue  
Suite 2400  
Austin, TX 78701